Iohexol products (contrast media) may currently be unavailable or available in limited supply due to the shutdown of a production facility in Shanghai, China during a Coronavirus Disease 2019 (COVID-19) lockdown. The facility is open, and production has resumed; however, the shortage is expected to continue until late June 2022. As a result of the iohexol shortage, the availability of other contrast agents may be affected as organizations seek other suitable alternatives.

Various nationally recognized organizations have developed guidance on strategies for conserving contrast media. The California Department of Public Health recommends facilities refer to the following guidance for actions to consider in managing the shortage:

• American Society of Health System Pharmacists (ASHP) - Considerations for Imaging Contrast Shortage Management and Conservation 
• American College of Radiology (ACR) - Statement from the ACR Committee on Drugs and Contrast Media
• Food and Drug Administration (FDA) - Repackaging of Certain Human Drug Products by Pharmacies and Outsourcing Facilities (PDF)

Health facilities should contact their Medical and Health Operational Area Coordinator (MHOAC) and their Licensing and Certification District Office if their available supply of contrast media for critical use, where alternative agents/imaging cannot be used, falls below a two-week threshold. Refer to the MHOAC Program Contact Information (PDF) for a listing of coordinators.

If you have any questions about this AFL, please contact your local district office. 

Sincerely,

Original signed by Cassie Dunham

Cassie Dunham

Deputy Director